Business Standard

Analysts' corner

Ranbaxy Laboratories & Havells India

Related News

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

Read more on:   
|

Read More

Fund managers divided on high beta preference

Riding high on the crest of the reforms wave, the markets touched their highest closing levels since July 2011 during the week under review ...

Advertisements

Quick Links

 

Market News

Maruti Suzuki India, Axis Bank joins Rs 1-lakh-cr market-cap club

Axis Bank hits a record high of Rs 440, while Maruti Suzuki touched a new high of Rs 3,349 in intra-day deals on BSE.

Marksans Pharma surges on strong Q2 results

The stock rallied 6% to Rs 64 on NSE after reporting 56% yoy growth in net profit at Rs 31 crore in September quarter.

Markets continue winning streak; Sensex up 400 points

The 30-share Sensex is up 412 points at 27,758 and the 50-share Nifty has gained 119 points to trade at 8,288.

Copper down 0.2% on weak global cues

Metal for delivery in November shed 0.14%

Silver down 0.6% on weak global trend

Weak trend trend overseas, eroding demand for the precious metals, pulled down silver prices

Back to Top